3 October 2017Americas

FDA issues new guidance to boost generic competition

The US Food and Drug Administration (FDA) has issued new guidance as part of its bid to target the barriers to generic drug competition.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

FDA reveals further steps to encourage generic competition

3 January 2018 The US Food and Drug Administration revealed additional steps aimed at encouraging generic competition today.

FDA to increase drug competition and speed up ANDA reviews

28 June 2017 The US Food and Drug Administration has revealed plans to increase competition in the US market for prescription drugs, as well as to facilitate the entry of generic drugs into the market.

FDA targets barriers to generic competition

26 June 2017 The Food and Drug Administration has announced its intention to target the barriers to generic drug competition.

More on this story

FDA reveals further steps to encourage generic competition

3 January 2018 The US Food and Drug Administration revealed additional steps aimed at encouraging generic competition today.

FDA to increase drug competition and speed up ANDA reviews

28 June 2017 The US Food and Drug Administration has revealed plans to increase competition in the US market for prescription drugs, as well as to facilitate the entry of generic drugs into the market.

FDA targets barriers to generic competition

26 June 2017 The Food and Drug Administration has announced its intention to target the barriers to generic drug competition.

More on this story

FDA reveals further steps to encourage generic competition

3 January 2018 The US Food and Drug Administration revealed additional steps aimed at encouraging generic competition today.

FDA to increase drug competition and speed up ANDA reviews

28 June 2017 The US Food and Drug Administration has revealed plans to increase competition in the US market for prescription drugs, as well as to facilitate the entry of generic drugs into the market.

FDA targets barriers to generic competition

26 June 2017 The Food and Drug Administration has announced its intention to target the barriers to generic drug competition.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB